ANNEX 3 Linies.pdf - Fundació Institut d'Investigació en Ciències de ...

Alvarez, M; Lezcano, C; Ponton, JL; Bonafont, X
Study of granulocyte colony-stimulating factor use in an onco-haematology unit
PHARM WORLD SCI 2009-FEB; 31 (1): 126-126
IF: 0,919
Barnadas, A; Gil, M; Gonzalez, S; Tusquets, I; Munoz, M; Arcusa, A; Prieto, L; Margeli-Vila, M; Moreno, A
Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
BRIT J CANCER 2009-feb-03; 100 (3): 442-449
IF: 4,346
Bassas-Vila J,.
Patrones tumorales en dermatopatología (A)
PIEL 2009;24:446-450
Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García
Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E.
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic
lymphocytic leukemia.
J CLIN ONCOL 2009; 27(27):4578-84.
IF: 17,793
Carcereny, E; Moran, T; Felip, E; Borghaei, H; Fitzgerald, T; Clark, J; Guan, SH; Hsu, K; Beckman, R; Yan, L; Rosell, R; Johnson, DH
An open label, randomized phase I/IIA trial evaluating MK-0646, an anti-IGF-1R monoclonal antibody (MoAB), in combination with
erlotinib for patients with recurrent non-small cell lung cancer (NSCLC)
J THORAC ONCOL 2009-SEP; 4 (9): S445-S446
IF: 4,547
Cardenal, F; Moran, T; Queralt, C; Porta, R; Camps, C; Majem, M; Lopez-Vivanco, G; Isla, D; Provencio, M; Sanchez, JJ; Taron, M;
Rosell, R
Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutations
J THORAC ONCOL 2009-SEP; 4 (9): S324-S325
IF: 4,547
Cardona, AF; Reguart, N; Reveiz, L
Wood-Smoke Exposure (WSE) as a Predictor of Response and Survival in Erlotinib-Treated Non-small Cell Lung Cancer (NSCLC)
Patients
J THORAC ONCOL 2009-JAN; 4 (1): 142-143
IF: 4,547
De la Rubia J, Montesinos P, Martino R, Jarque I, Rovira M, Vázquez L, López J, Batlle M, de la Cámara R, Julià A, Lahuerta JJ,
Debén G, Díaz J, García R, Sanz MA.
Imipenm/cilastatin wtih or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation:
results of a Spanish multicenter study.
BIOL BLOOD MARROW TR 2009; 15: 512-516
IF: 3,149
Diez-Martin, JL; Balsalobre, P; Re, A; Michieli, M; Ribera, JM; Canals, C; Conde, E; Rosselet, A; Gabriel, I; Varela, R; Allione, B;
Cwynarski, K; Genet, P; Espigado, I; Biron, P; Schmitz, N; Hunter, AE; Ferrant, A; Guillerm, G; Hentrich, M; Jurado, M; Fernandez, P;
Serrano, D; Rossi, G; Sureda, A
Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral
blood stem cell transplantation
BLOOD 2009-juny-04; 113 (23): 6011-6014
IF: 10,555
Estevez, LG; Fortes, JL; Adrover, E; Peiro, G; Margeli, M; Castella, E; Cuevas, JM; Bernet, L; Segui, MA; Andreu, X
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of
biological markers in a GEICAM phase II study
CLIN TRANSL ONCOL 2009-JAN; 11 (1): 54-59
IF: 1,146
Pàgina 33 de 67